REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Tue, 14th Dec 2021 18:01

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cohort PLC - defence and security markets-focussed technology company - For the six months ended October 31, pretax loss widens to GBP1.7 million from GBP370,000 a year before, due to higher administrative costs more than offsetting a 10% year-on-year increase in revenue to GBP60.0 million from GBP54.4 million. Order intake rose 18% to GBP105.3 million from GBP89.2 million, alongside a record closing order book of GBP285.8 million. Declares interim dividend of 3.85 pence per share, up 10% from 3.50p. Looking ahead, expects Chess order intake and delivery issues to affect the group's performance for the financial year.

----------

BMO Global Smaller Cos PLC - investment firm focused on on a portfolio of global smaller companies - As at October 31, net asset value per share increases 37% year-on-year to 183.62 pence from 134.49p. NAV total return for the period is 5.6%, compared to a 4.3% return from the benchmark, comprising 30% Numis UK Smaller Companies ex investment companies Index and 70% MSCI World All Countries ex UK Small Cap Index. Declares interim dividend of 0.57p per share, up 3.6% from 0.55p a year prior.

----------

Henderson Diversified Income Trust PLC - Janus Henderson managed trust seeking income and capital growth - As at October 31, net asset value per share increases 1.8% to 91.42 pence from 89.83p the same date a year before. NAV total return at 1.9%, compared to a 1.3% return from its benchmark, comprising 60% Global High Yield Credit, 25% Global Investment Grade Corporate Credit and 15% European Loans. Dividend per share for the six month period remains in line at 4.40p.

----------

GRC International Group PLC - Ely, England-based products and services for IT governance, risk management and compliance - For the six months ended September 30, pretax loss narrows to GBP492,000 from GBP1.5 million the same period a year before, on revenue which grew 22% year-on-year to GBP6.6 million from GBP5.4 million. Billings increases 27% to GBP7.1 million from GBP5.6 million, with the Software-as-a-Service rising on a boost in customers amid high demand. Looking ahead, expects strong trading momentum to continue into second half of the financial year.

----------

Miton UK MicroCap Trust PLC - investment firm focused on company's with market cap of less than GBP150 million - Net asset value per share as at October 31 increases 55% year-on-year to 96.67 pence from 62.32p. However for the six month period, NAV total return declined 7.8%, compared to 1.4% rise from the Numis 1000 Index.

----------

Begbies Traynor Group PLC - corporate restructuring specialist - For the six months ended October 31, pretax profit hikes to GBP2.7 million from GBP451,000 the same period a year before, on revenue which grew 39% year-on-year to GBP52.3 million from GBP37.5 million, through new acquisitions including MAF Finance and Fernie Greaves Chartered Surveyors and in comparison to a prior period affected by the lockdown. Declares interim dividend of 1.1 pence per share, up 10% from 1.0p the prior year. Looking ahead, expects annual results to be in line with market expectations.

----------

Surface Transforms PLC - Liverpool-based ​​carbon fibre reinforced ceramic brake discs maker - Expects revenue for 2021 to be below GBP3 million, and significantly short of market expectations, due to a results of delays in the final commissioning of the upscaled production capacity at Knowsley. Although these capacity issues have been narrowed down to one complex furnace, which is on-track to be resolved immediately, Surface Transforms is unlikely to recover the sales gap in 2021, due to December being "a short month".

----------

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - For the six months ended September 30, pretax loss narrows to GBP449,022 from GBP475,874 the same period a year before, as lower costs more than offset revenue dropping to GBP50,000 from GBP195,550. Revenue came from the second instalment of the upfront payment from Oxilio on the full licensing agreement for NXP001. Company plans to raise GBP1.7 million through a subscription of 110.0 million shares by Lanstead Capital Investors LP at 1.5 pence each, the proceeds of which will go towards the development of NXP002 and NXP004.

----------

Trellus Health PLC - White Plains, New York-based digital health platform for complex chronic conditions - For 2021, company expects to incur a loss before interest, tax, depreciation and amortisation of USD5.9 million, on revenue of USD25,000. As at December 31, year-end cash is expected to be at least USD30 million, rising above market expectations.

----------

Yourgene Health PLC - molecular diagnostics firm - For the six months ended September 30, pretax loss narrows to GBP306,000 from GBP2.6 million the same period a year prior, due to revenue more than doubling to GBP17.5 million from GBP8.2 million through a sharp rise in Genomic Services through the high volume of Covid-19 testing services. Looking ahead, expects revenue for the financial year to further exceed market expectations. In addition, Yourgene wins a contract for the provision of genetic sequencing services by the UK Health Security Agency, which will run until March 31.

----------

Majedie Investments PLC - London-based investment trust - As at September 30, net asset value per share increases 16% year-on-year to 287.1 pence from 247.7p the same date the year before. For the annual period, net asset value total return was 20.6%. compared to the FTSE All-Share Index, which returned 27.9% and the MSCI All Country Index, which returned 22.1%. Declares final dividend of 7.0 pence per share, in line with year before.

----------

Jupiter Green Investment Trust PLC - investment firm focused on companies which have a significant focus on environmental solutions - Net asset value per share as at September 30 increased to 277.38 pence from 258.24p at the end of March. NAV total return is 4.6%, reflecting an underperformance against the MSCI World Small Cap Total Return Index, which returned 6.7%.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Oct 2019 12:27

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Read more
10 Sep 2019 13:47

Nuformix Chief Financial Officer Kirk Siderman-Wolter Resigns Abruptly

(Alliance News) - Pharmaceutical company Nuformix PLC on Tuesday said Chief Financial Officer and Senior Independent Non-Executive Director Kirk Siderman-Wolter has resigned with immediate company

Read more
9 Sep 2019 11:25

Nuformix, Ebers Tech File Patent For Cannabinoid Cocrystals

(Alliance News) - Pharmaceutical company Nuformix PLC on Monday said it and partner Ebers Tech Inc have filed the first patent in relation to cannabinoid cocrystals.The patented cannabinoid

Read more
6 Sep 2019 12:17

Nuformix Hires Cambridge Interstitial Lung Disease Unit Lead Clinician

(Alliance News) - Nuformix PLC said on Friday it has appointed Muhunthan Thillai to its scientific advisory board with immediate effect.Thillai is the lead clinician for the Cambridge Lung

Read more
18 Jul 2019 11:16

Nuformix Annual Loss Narrows As Revenue Jumps On NXP001 Progress

(Alliance News) - Nuformix PLC on Thursday said its revenue multiplied in its most recently-ended financial year as it has secured its first licensing income from NXP001.NXP001 is one of in

Read more
30 May 2019 10:33

WINNERS & LOSERS SUMMARY: De La Rue Down As CEO Exits And Profit Falls

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - LOSERS----------National a

Read more
30 May 2019 10:14

Nuformix Shares Jump On Positive NXP001 Clinical Study Results

LONDON (Alliance News) - Shares in Nuformix PLC surged on Thursday as the company reported positive results in its clinical study of NXP001.Nuformix shares were trading 30% higher at 13.50

Read more
9 Apr 2019 11:25

Nuformix inks cannabinoid therapeutics deal with Ebers Tech

(Sharecast News) - Pharmaceutical development company Nuformix has inked an agreement for cannabinoid therapeutics development, licensing and commercialisation with Canadian outfit Ebers Tech.

Read more
9 Apr 2019 10:46

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo up -

Read more
22 Mar 2019 08:50

Nuformix Doses First Patient In NXP001 Anti-Nausea Drug Trial

LONDON (Alliance News) - Nuformix PLC on Friday said it has begun clinical studies for its anti-nausea drug NXP001 and dosed its first patient.Shares in Nuformix were down 4.6% at 2.10 on a

Read more
27 Feb 2019 10:48

MHRA gives go-ahead to Nuformix for human studies

(Sharecast News) - Pharmaceutical development company Nuformix has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin human pharmacokinetics studies for its lead asset, NXP001, it announced on Wednesday.

Read more
3 Dec 2018 09:53

Nuformix Reports Positive Results From NXP002 Pre-Clinical Trial

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC on Monday reported positive results from its completed NXP002 fibrosis programme pre-clinical trial for the treatment of a of

Read more
27 Nov 2018 10:04

Nuformix Expands NXP001 Agreement With Additional Pre-Clinical Study

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC said on Tuesday it has expanded its current licensing agreement with partner Newsummit Biopharma for the development of cancer

Read more
14 Sep 2018 10:17

Nuformix Rises As NXP001 Passes "Major" Pre-Clinical Milestone

LONDON (Alliance News) - Shares in pharmaceutical firm Nuformix PLC rose Friday it has received a GBP500,000 payment after its NXP001 product reached a pre-clinical milestone.Nuformix was a

Read more
12 Sep 2018 16:00

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 SeptemberBahamas PetroleumFlybe GroupBetter Capital PCCWorldwide 14 UK 17

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.